PRESS RELEASE

from ABIVAX (EPA:ABVX)

ABIVAX Announces Termination of Liquidity Contract and Publishes End of Contract Statement.

ABIVAX
ABIVAX Announces Termination of Liquidity Contract and Publishes End of Contract Statement.

11-Oct-2024 / 18:00 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


 

Abivax Announces Termination of Liquidity Contract and Publishes End of Contract Statement

PARIS, France, October 11, 2024, 6:00 p.m. (CEST) - Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients witch chronic inflammatory diseases, today announced that it has ended the liquidity contract signed on February 4, 2019 with TRADITION SECURITIES AND FUTURE (TSAF SA). The termination is effective from September 30, 2024, after the close of Euronext market.

On the termination date of this contract, the following assets appeared on the liquidity account:

  • 0 shares
  • €434,377.26 in cash

As a reminder, for the latest half-year statement as of June 30, 2024, the following assets appeared on the liquidity account:

  • 11,431 shares
  • €313,753.00 in cash

And between July 1st, 2024, and September 30, 2024, included:

 

Buy side

Traded volume :

1,070 shares

€12,014.60

10 transactions

Sell side

Traded volume :

12,501 shares

€132,638.86

26 transactions

Moreover, the following resources were allocated to the liquidity contract for its implementation beginning June 26th, 2015 (date of the initial contract entered into between the Company and TSAF SA, which was replaced by the above-mentioned contract):

  • 0 shares
  • €1,000,000 in cash

The liquidity account returned €500,000.00 in cash to Abivax on April 15, 2020.

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Based in France and the U.S., Abivax’ s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com. Follow us on X, formerly Twitter, @ABIVAX.

Contacts

 

Abivax

Finance department

Didier Blondel
didier.blondel@abivax.com
+33 1 53 83 08 41

Investor Relations France Seitosei ● Actifin

Ghislaine Gasparetto

ghislaine.gasparetto@seitosei-actifin.com

+33 6 21 10 49 24

 

Abivax

Investor Relations
Patrick Malloy
patrick.malloy@abivax.com
+1 847 987 4878

 


Regulatory filing PDF file

File: 20241011_Abivax_Termination of liquidity contract and end of contract statement


Language:English
Company:ABIVAX
5, Rue de La Baume
75008 Paris
France
E-mail:info@abivax.de
Internet:www.abivax.de
ISIN:FR0012333284
Euronext Ticker:ABVX
AMF Category:Share buyback / Disposal of own shares / Information relating to the liquidity contract
EQS News ID:2007167
 
End of AnnouncementEQS News Service

2007167  11-Oct-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2007167&application_name=news&site_id=symex~~~af100301-a623-4c64-8f3d-90fc88eca9e6
See all ABIVAX news